Cervical cancer wiped out by pioneering use of ‘amazing’ osteoporosis drugs

Mail Online

United Kingdom

By Fiona Macrae
Last updated at 8:56 AM on 10th November 2009

Cervical cancer can be destroyed by drugs used to treat breast cancer and osteoporosis, a study suggests.

In results described as ‘amazing’ by researchers, one of the treatments eliminated the cancer in 11 out of 13 cases.

The results are hugely important because, despite advances in medicine, cervical cancer still affects almost 3,000 British women a year and kills more than 1,000.

Half a million women are diagnosed with it each year worldwide, but only 50 per cent will survive.

Britain and other countries have recently started to vaccinate teenage girls against the cancer. But the programme is in its infancy and the jab will not prevent all cases.

The latest research centres on fulvestrant, which is normally used to treat breast cancer, and raloxifene, used for osteoporosis.

Importantly, the drugs have already been deemed safe for use, meaning they could be marketed as cervical cancer treatments much more quickly than newly-discovered medicines.

The initial results come from experiments in mice. But if the success is repeated in women, the drugs could be in widespread use as cervical cancer treatments within just five years.

The researchers, from the University of Wisconsin-Madison in the U.S., started by showing that the growth of cervical tumours, like many breast cancers, is fuelled by the sex hormone oestrogen.
Read more: http://www.dailymail.co.uk/health/article-1226440/Cervical-cancer-wiped-pioneering-use-amazing-osteoporosis-drugs.html#ixzz0Wnl9vgUQ


Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.